In one paragraphArticle in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Krisztina BodnárDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.
Christelle MarminonGastroenterology and Technologies for Health Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, University of Lyon, 69373 Lyon, France.ORCID 0000-0002-4043-3949 Ádám HaimhofferDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.ORCID 0000-0003-2123-5821 Boglárka PappDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.ORCID 0009-0005-1750-4496 Pálma FehérDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.
Zoltán UjhelyiDepartment of Industrial Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Rex Ferenc Utca 1, 4002 Debrecen, Hungary.ORCID 0000-0001-9724-0614 Joachim JoseInstitute of Pharmaceutical and Medicinal Chemistry, University of Münster, 48149 Münster, Germany.ORCID 0000-0002-0666-2676 Marc Le BorgneGastroenterology and Technologies for Health Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, University of Lyon, 69373 Lyon, France.ORCID 0000-0003-1398-075X Ildikó BácskayDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.ORCID 0000-0001-8663-2890 Liza JózsaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.ORCID 0000-0001-5835-5304 Funding
French Ministry for Europe and Foreign Affairs PHC BALATON programme (nanoABCG2+, project number: 51497VD)National Research, Development and Innovation Office 2023-1.2.4-TÉT-2023-00003
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
ABCG2 inhibitorbioavailabilitybiocompatibilityCaco-2drug delivery systemsMCF-7microencapsulationpolyvinylpyrrolidone
Identifiers
PMID41471102
PMCPMC12737036
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390